Vol 72, No 2 (2021)
Review paper
Published online: 2021-04-30

open access

Page views 1745
Article views/downloads 1221
Get Citation

Connect on Social Media

Connect on Social Media

Selected thyreology problems during the COVID-19 pandemic. Hypothyroidism and hyperthyroidism — did anything change?

Beata Matyjaszek-Matuszek1, Magdalena Woźniak1, Alicja Ochmańska2, Nadia Sawicka-Gutaj2, Marek Ruchała2, Agata Czarnywojtek23
Pubmed: 33970482
Endokrynol Pol 2021;72(2):170-178.


On March 11, 2020, the World Health Organisation (WHO) observed the scale of epidemic risk and declared the state of the COVID-19 pandemic. Most countries, including Poland, implemented national and local emergency management plans to deal with the imminent threat of SARS-CoV-2 infection, one of the most serious in this century, according to many experts. In the era of pandemic, during which an epidemiological regime and social distancing are constantly recommended, and routine medical care and planned surgical procedures have been postponed or significantly reduced, patients and their physicians have to struggle on a daily basis with difficult access to diagnostic and therapeutic procedures. This is a great challenge for both groups. The aim of this study is to assess the current state of knowledge about thyreological diseases during the COVID-19 pandemic and to provide indications for the introduced therapeutic changes on the basis of recent scientific literature published up to December 2020 and searches of the PubMed, Google Scholar, EMBASE, and Web of Science databases, which searched for keywords related to SARS-CoV-2 and its influence on thyreology problems. The main focus was on diagnostic and therapeutic differences in the era of the COVID-19 pandemic, bearing in mind the most common endocrinopathies, i.e. hypothyroidism and hyperthyroidism, as well as advantages and disadvantages and possibilities of using telemedicine in the common practice of a specialist physician.

Article available in PDF format

View PDF Download PDF file


  1. WHO Director-General's opening remarks at the media briefing on COVID-19 — 11 March 2020. https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020.
  2. Yan Y, Yang F, Zhu X, et al. Analysis of clinical features and pulmonary CT features of coronavirus disease 2019 (COVID-19) patients with diabetes mellitus. Endokrynol Pol. 2020; 71(5): 367–375.
  3. Koronawirus: informacje i zalecenia. https://www.gov.pl/web/koronawirus/wykaz-zarazen-koronawirusem-sars-cov-2.
  4. Pierwszy przypadek koronawirusa w Polsce. https://www.gov.pl/web/zdrowie/pierwszy-przypadek-koronawirusa-w-polsce.
  5. Boelaert K, Visser WE, Taylor PN, et al. ENDOCRINOLOGY IN THE TIME OF COVID-19: Management of hyperthyroidism and hypothyroidism. Eur J Endocrinol. 2020; 183(1): G33–G39.
  6. Pal R, Bhadada SK. Managing common endocrine disorders amid COVID-19 pandemic. Diabetes Metab Syndr. 2020; 14(5): 767–771.
  7. Taylor PN, Albrecht D, Scholz A, et al. Global epidemiology of hyperthyroidism and hypothyroidism. Nat Rev Endocrinol. 2018; 14(5): 301–316.
  8. Peeters RP. Subclinical Hypothyroidism. N Engl J Med. 2017; 376(26): 2556–2565.
  9. Garmendia Madariaga A, Santos Palacios S, Guillén-Grima F, et al. The incidence and prevalence of thyroid dysfunction in Europe: a meta-analysis. J Clin Endocrinol Metab. 2014; 99(3): 923–931.
  10. Chaker L, Bianco A, Jonklaas J, et al. Hypothyroidism. Lancet. 2017; 390(10101): 1550–1562.
  11. Hannemann A, Friedrich N, Haring R, et al. Thyroid function tests in patients taking thyroid medication in Germany: Results from the population-based Study of Health in Pomerania (SHIP). BMC Res Notes. 2010; 3: 227.
  12. Parle JV, Franklyn JA, Cross KW, et al. Thyroxine prescription in the community: serum thyroid stimulating hormone level assays as an indicator of undertreatment or overtreatment. Br J Gen Pract. 1993; 43(368): 107–109.
  13. Somwaru LL, Arnold AM, Joshi N, et al. High frequency of and factors associated with thyroid hormone over-replacement and under-replacement in men and women aged 65 and over. J Clin Endocrinol Metab. 2009; 94(4): 1342–1345.
  14. Stangierski A, Ruchała M, Krauze T, et al. Treatment of severe thyroid function disorders and changes in body composition. Endokrynol Pol. 2016; 67(4): 359–366.
  15. Ross DS, Daniels GH, Gouveia D. The use and limitations of a chemiluminescent thyrotropin assay as a single thyroid function test in an out-patient endocrine clinic. J Clin Endocrinol Metab. 1990; 71(3): 764–769.
  16. Novel Coronavirus (COVID-19) and the Thyroid: Frequently Asked Questions. https://www thyroid org/covid-19/coronavirus-frequently.
  17. COVID-19: Information and Recommendations for Patients with Thyroid Diseases. https://www.eurothyroid.com/files/download/ETA-PHB.pdf.
  18. Stockigt J. Clinical Strategies in the Testing of Thyroid Function. In: Feingold KR, Anawalt B, Boyce A. ed. Endotext. MDText, South Dartmouth 2000.
  19. Biondi B, Wartofsky L. Treatment with thyroid hormone. Endocr Rev. 2014; 35(3): 433–512.
  20. Nair R, Mahadevan S, Muralidharan RS, et al. Does fasting or postprandial state affect thyroid function testing? Indian J Endocrinol Metab. 2014; 18(5): 705–707.
  21. Sheehan MT. Biochemical Testing of the Thyroid: TSH is the Best and, Oftentimes, Only Test Needed - A Review for Primary Care. Clin Med Res. 2016; 14(2): 83–92.
  22. Gietka-Czernel M, Hubalewska-Dydejczyk A, Kos-Kudła B, et al. Expert opinion on liquid L-thyroxine usage in hypothyroid patients and new liquid thyroxine formulation — Tirosint SOL. Endokrynol Pol. 2020; 71(5): 441–465.
  23. Benvenga S, Carlé A. Levothyroxine Formulations: Pharmacological and Clinical Implications of Generic Substitution. Adv Ther. 2019; 36(Suppl 2): 59–71.
  24. Yue CS, Scarsi C, Ducharme MP. Pharmacokinetics and potential advantages of a new oral solution of levothyroxine vs. other available dosage forms. Arzneimittelforschung. 2012; 62(12): 631–636.
  25. Pirola I, Gandossi E, Brancato D, et al. TSH evaluation in hypothyroid patients assuming liquid levothyroxine at breakfast or 30 min before breakfast. J Endocrinol Invest. 2018; 41(11): 1301–1306.
  26. Fallahi P, Ferrari SM, Camastra S, et al. TSH Normalization in Bariatric Surgery Patients After the Switch from L-Thyroxine in Tablet to an Oral Liquid Formulation. Obes Surg. 2017; 27(1): 78–82.
  27. Vita R, Di Bari F, Benvenga S. Oral liquid levothyroxine solves the problem of tablet levothyroxine malabsorption due to concomitant intake of multiple drugs. Expert Opin Drug Deliv. 2017; 14(4): 467–472.
  28. Peroni E, Vigone MC, Mora S, et al. Congenital hypothyroidism treatment in infants: a comparative study between liquid and tablet formulations of levothyroxine. Horm Res Paediatr. 2014; 81(1): 50–54.
  29. Cappelli C, Negro R, Pirola I, et al. Levothyroxine liquid solution versus tablet form for replacement treatment in pregnant women. Gynecol Endocrinol. 2016; 32(4): 290–292.
  30. Trimboli P, Virili C, Centanni M, et al. Thyroxine Treatment With Softgel Capsule Formulation: Usefulness in Hypothyroid Patients Without Malabsorption. Front Endocrinol (Lausanne). 2018; 9: 118.
  31. Tariq A, Wert Y, Cheriyath P, et al. Effects of Long-Term Combination LT4 and LT3 Therapy for Improving Hypothyroidism and Overall Quality of Life. South Med J. 2018; 111(6): 363–369.
  32. Samuels MH, Kolobova I, Niederhausen M, et al. Effects of Altering Levothyroxine (L-T4) Doses on Quality of Life, Mood, and Cognition in L-T4 Treated Subjects. J Clin Endocrinol Metab. 2018; 103(5): 1997–2008.
  33. Biondi B, Wartofsky L. Combination treatment with T4 and T3: toward personalized replacement therapy in hypothyroidism? J Clin Endocrinol Metab. 2012; 97(7): 2256–2271.
  34. Idrees T, Palmer S, Maciel RMB, et al. Liothyronine and Desiccated Thyroid Extract in the Treatment of Hypothyroidism. Thyroid. 2020; 30(10): 1399–1413.
  35. Leese GP, Soto-Pedre E, Donnelly LA. Liothyronine use in a 17 year observational population-based study - the tears study. Clin Endocrinol (Oxf). 2016; 85(6): 918–925.
  36. Wiersinga WM, Duntas L, Fadeyev V, et al. 2012 ETA Guidelines: The Use of L-T4 + L-T3 in the Treatment of Hypothyroidism. Eur Thyroid J. 2012; 1(2): 55–71.
  37. Garmendia Madariaga A, Santos Palacios S, Guillén-Grima F, et al. The incidence and prevalence of thyroid dysfunction in Europe: a meta-analysis. J Clin Endocrinol Metab. 2014; 99(3): 923–931.
  38. Hollowell JG, Staehling NW, Flanders WD, et al. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab. 2002; 87(2): 489–499.
  39. Taylor PN, Albrecht D, Scholz A, et al. Global epidemiology of hyperthyroidism and hypothyroidism. Nat Rev Endocrinol. 2018; 14(5): 301–316.
  40. Cooper D. Hyperthyroidism. Lancet. 2003; 362(9382): 459–468.
  41. Boelaert K, Torlinska B, Holder RL, et al. Older subjects with hyperthyroidism present with a paucity of symptoms and signs: a large cross-sectional study. J Clin Endocrinol Metab. 2010; 95(6): 2715–2726.
  42. National Guideline Centre (UK).. Thyroid disease: assessment and management. National Institute for Health and Care Excellence, London 2019.
  43. Abraham P, Avenell A, Watson WA, et al. Antithyroid drug regimen for treating Graves' hyperthyroidism. Cochrane Database Syst Rev. 2003(4): CD003420.
  44. Andersen SL, Olsen J, Laurberg P. Antithyroid Drug Side Effects in the Population and in Pregnancy. J Clin Endocrinol Metab. 2016; 101(4): 1606–1614.
  45. Ross DS, Burch HB, Cooper DS, et al. 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis. Thyroid. 2016; 26(10): 1343–1421.
  46. Burch HB, Cooper DS. Management of Graves Disease: A Review. JAMA. 2015; 314(23): 2544–2554.
  47. Bartalena L, Baldeschi L, Boboridis K, et al. European Group on Graves' Orbitopathy (EUGOGO). The 2016 European Thyroid Association/European Group on Graves' Orbitopathy Guidelines for the Management of Graves' Orbitopathy. Eur Thyroid J. 2016; 5(1): 9–26.
  48. Taylor PN, Zhang L, Lee RWJ, et al. New insights into the pathogenesis and nonsurgical management of Graves orbitopathy. Nat Rev Endocrinol. 2020; 16(2): 104–116.
  49. Guidance on shielding and protecting people who are clinically extremely vulnerable from COVID-19. https://www gov uk/government/publications/guidance-on-shielding-and-protecting-extremely-vulnerable-persons-from-covid-19/guidance-on-shielding-and-protecting-extremely-vulnerable-persons-from-covid-19.
  50. Kahaly GJ, Bartalena L, Hegedüs L, et al. 2018 European Thyroid Association Guideline for the Management of Graves' Hyperthyroidism. Eur Thyroid J. 2018; 7(4): 167–186.
  51. Xia J, Tong J, Liu M, et al. Evaluation of coronavirus in tears and conjunctival secretions of patients with SARS-CoV-2 infection. J Med Virol. 2020; 92(6): 589–594.
  52. Coronavirus (COVID-19), pregnancy and women’s health. https://www.rcog.org.uk/en/guidelines-research-services/coronavirus-covid-19-pregnancy-and-womens-health/.
  53. Stagnaro-Green A, Abalovich M, Alexander E, et al. American Thyroid Association Taskforce on Thyroid Disease During Pregnancy and Postpartum. Guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and postpartum. Thyroid. 2011; 21(10): 1081–1125.
  54. Andersen SL, Andersen S. Antithyroid drugs and birth defects. Thyroid Res. 2020; 13: 11.